H. Anne Pereira, Ph.D.

---

Summary

My laboratory investigates the role of a novel inflammatory mediator known as CAP37. We focus on the significance of this protein in host defense against severe infections including infections of the eye and in various inflammatory mediated diseases such as atherosclerosis and Alzheimer's disease. We currently employ a combination of cellular, immunological, biochemical and molecular approaches at the in vitro and in vivo level to solve these questions. Our long-term goals are to design new and effective antibiotics and anti-inflammatory therapeutics.

---

Research

This laboratory investigates the role of a novel inflammatory mediator known as CAP37. We focus on the significance of this protein in host defense against severe infections including infections of the eye and in various inflammatory mediated diseases such as atherosclerosis and Alzheimer's disease. We currently employ a combination of cellular, immunological, biochemical and molecular approaches at the in vitro and in vivo level to solve these questions. Our long-term goals are to design new and effective antibiotics and anti-inflammatory therapeutics.

Patents

---

Publications & Presentations

41. Pereira H A, Spitznagel J K, Winton E F, Shafer W M, Martin L E, Guzman G S, Pohl J, Scott R W, Marra M N, Kinkade, Jr J M. The ontogeny of a 57-Kd cationic antimicrobial protein of human polymorphonuclear leukocytes: localization to a novel granule population. Blood. 1990; 76 : 825-34

42. Pereira H A, Shafer W M, Pohl J, Martin L E, Spitznagel J K. CAP37, a human neutrophil-derived chemotactic factor with monocyte specific activity. The Journal of clinical investigation. 1990; 85 : 1468-76

43. Pereira H A, Spitznagel J K, Pohl J, Wilson D E, Morgan J, Palings I, Larrick J W. CAP 37, a 37 kD human neutrophil granule cationic protein shares homology with inflammatory proteinases. Life sciences. 1990; 46 : 189-96

44. Pereira H A, Martin L E, Spitznagel J K. Quantitation of a cationic antimicrobial granule protein of human polymorphonuclear leukocytes by ELISA. Journal of immunological methods. 1989; 117 : 115-20

45. Spitznagel J K, Pereira H A, Martin L E, Guzman G S, Shafer W M. A monoclonal antibody that inhibits the antimicrobial action of a 57 KD cationic protein of human polymorphonuclear leukocytes. Journal of immunology (Baltimore, Md. : 1950). 1987; 139 : 1291-6

Grants

1. Oklahoma Shared Clinical and Translational Resources. NIH. Start Date: 2023. End Date: 2028.

2. Vision Science Training Program. NIH. Start Date: 2021. End Date: 2026.

3. STTR Phase 1: Multi-target Peptide Drug for Alzheimer's Disease. NIA. Start Date: 2024. End Date: 2025.

4. STTR Phase 1: Novel Ophthalmic Product for Corneal Infections and Injuries. NIH. Start Date: 2021. End Date: 2023.

5. Oklahoma Shared Clinical and Translational Resources. NIH. Start Date: 2018. End Date: 2023.

Awards and Honors

1. University of Oklahoma Health Sciences Center. David L Boren Professorship. Date: 2018.


2. College of Pharmacy. Herbert and Dorothy Langsam Chair. Date: 2018.


3. Oklahoma BioScience Association. OK Bio Researcher Recognition Award -Winner. Date: 2016.


4. Journal Record. Journal Record Innovator of the Year. Date: 2016.


5. National Academy of Inventors. Fellow. Date: 2015.

Education

1. Degree: Ph D. University of Melbourne. Date: 1982.


2. Degree: BSc (Honours) First class honours & First Place. University of Melbourne. Date: 1976.


3. Degree: BS. University of Melbourne. Date: 1975.

Administrative Assignments

1. Role: Dean. Scope: University. Description: Dean of the Graduate College. Responsible for Graduate Programs on the Health Sciences Campus and the Postdoctoral Office. Date: 2014.
Read More
2. Role: Associate Dean. Scope: College. Description: Responsible for Oversight of research activities in the College of Pharmacy, mentoring junior faculty and trainees. Date: 2009.
Read More